Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$21.43 -5.6%	$21.74	$17.24 ▼ $27.94	$13.75B	0.95	1.11 million shs	1.75 million shs
RDY Dr. Reddy's Laboratories	$13.82 +1.6%	$14.85	$12.26 ▼ $16.89	$11.52B	0.29	1.52 million shs	1.11 million shs
TEVA Teva Pharmaceutical Industries	$16.34 +0.3%	$16.72	$12.47 ▼ $22.80	$18.74B	0.62	13.05 million shs	9.53 million shs
TGTX TG Therapeutics	$26.71 -4.2%	$36.10	$19.45 ▼ $46.48	$4.24B	1.95	2.57 million shs	4.79 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	-1.61%	+0.14%	+7.53%	-18.92%
RDY Dr. Reddy's Laboratories	0.00%	-0.97%	-4.79%	-0.79%	-17.72%
TEVA Teva Pharmaceutical Industries	0.00%	+6.24%	-0.31%	-8.80%	-6.25%
TGTX TG Therapeutics	0.00%	-23.73%	-27.97%	-23.66%	+34.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.6969 of 5 stars	3.3	3.0	0.0	0.0	3.9	0.0	3.1
RDY Dr. Reddy's Laboratories	2.5357 of 5 stars	2.5	2.0	1.7	0.0	3.4	0.0	1.9
TEVA Teva Pharmaceutical Industries	2.9536 of 5 stars	3.6	2.0	0.0	0.0	2.8	1.7	1.3
TGTX TG Therapeutics	4.0003 of 5 stars	3.4	0.0	0.0	3.5	2.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	76.39% Upside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	22.69% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	51.25% Upside
TGTX TG Therapeutics	2.75	Moderate Buy	$46.25	73.16% Upside

Current Analyst Ratings Breakdown

Latest TGTX, TEVA, GMAB, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.26B	4.22	$1.52 per share	14.13	$8.04 per share	2.67
RDY Dr. Reddy's Laboratories	$334.26B	0.03	$1.03 per share	13.36	$4.73 per share	2.92
TEVA Teva Pharmaceutical Industries	$16.54B	1.13	$3.36 per share	4.87	$4.74 per share	3.45
TGTX TG Therapeutics	$329M	12.89	$0.12 per share	222.65	$1.43 per share	18.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.99	10.77	12.04	6.35	37.53%	21.03%	16.98%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	20.93	16.85	5.52	16.99%	17.25%	11.63%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.21	0.97	-0.95%	46.10%	7.18%	N/A
TGTX TG Therapeutics	$23.38M	$0.37	72.19	26.71	N/A	13.31%	27.83%	9.96%	N/A

Latest TGTX, TEVA, GMAB, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.32	$0.17	-$0.15	$0.17	$147.76 million	$141.15 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
7/23/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.18	$0.20	+$0.02	$0.20	$88.27 billion	$988.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.51%	N/A	10.61%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	6.22	6.20
RDY Dr. Reddy's Laboratories	0.01	1.89	1.36
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
RDY Dr. Reddy's Laboratories	3.85%
TEVA Teva Pharmaceutical Industries	54.05%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
RDY Dr. Reddy's Laboratories	2.00%
TEVA Teva Pharmaceutical Industries	0.55%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

TGTX, TEVA, GMAB, and RDY Headlines

Recent News About These Companies

Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

August 10 at 7:35 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

August 10 at 3:50 AM | marketbeat.com

What is B. Riley's Estimate for TG Therapeutics Q3 Earnings?

August 9 at 2:21 AM | americanbankingnews.com

TG Therapeutics files automatic mixed securities shelf

August 9 at 2:45 AM | msn.com

Beyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)

August 8 at 12:15 AM | gurufocus.com

What is B. Riley's Forecast for TG Therapeutics Q3 Earnings?

August 8 at 8:02 AM | marketbeat.com

What is B. Riley's Forecast for TG Therapeutics Q4 Earnings?

August 8 at 3:37 AM | americanbankingnews.com

FY2025 EPS Estimate for TG Therapeutics Reduced by Analyst

August 8 at 2:41 AM | americanbankingnews.com

B. Riley Has Bullish Outlook for TG Therapeutics Q4 Earnings

August 7, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings

August 7, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $43.80 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook

August 6, 2025 | msn.com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

August 6, 2025 | msn.com

Federated Hermes Inc. Sells 64,385 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

August 6, 2025 | marketbeat.com

Investors Purchase High Volume of Call Options on TG Therapeutics (NASDAQ:TGTX)

August 6, 2025 | americanbankingnews.com

TG Therapeutics (NASDAQ:TGTX) Shares Gap Down Following Weak Earnings

August 6, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

August 5, 2025 | insidermonkey.com

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

August 5, 2025 | zacks.com

Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

August 5, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Shares Gap Down After Earnings Miss

August 5, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, TEVA, GMAB, and RDY Company Descriptions

Genmab A/S NASDAQ:GMAB

$21.43 -1.26 (-5.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$20.84 -0.59 (-2.77%)

As of 08:10 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Dr. Reddy's Laboratories NYSE:RDY

$13.82 +0.22 (+1.58%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$13.80 -0.01 (-0.07%)

As of 08/8/2025 06:40 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries NYSE:TEVA

$16.34 +0.05 (+0.31%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$16.28 -0.06 (-0.37%)

As of 08:12 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TG Therapeutics NASDAQ:TGTX

$26.71 -1.18 (-4.23%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$26.50 -0.21 (-0.79%)

As of 08:13 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time